# Tessera Therapeutics

Gene Writing platform using engineered mobile genetic elements to write therapeutic sequences into the genome (preclinical platform).


Source: https://cn.bioecon.ru/companies/tessera-therapeutics/
Updated: 2026-07-29

- 国家: United States

## 可核验事实

| 事实 | 数值 | 来源 |
| --- | --- | --- |
| 员工人数 | 185名员工 | https://menfem.com/companies/tessera, https://usearch.com/company/tessera-therapeutics/overview |
| 营收 | 年营收$43.5M [中等置信度] | https://usearch.com/company/tessera-therapeutics/overview |
| 监管批准 | TSRA-196 的 IND 申请获 FDA 许可（2026年1月） | https://www.tesseratherapeutics.com/news/tessera-therapeutics-announces-fda-clearance-of-ind-application-for-its-lead-in-vivo-gene-editing-program-tsra-196-for-aatd |
| 产能 | 无（公司没有自有生产设施） [中等置信度] | https://menfem.com/companies/tessera |
| 生产基地 | 无（外包给CDMO供应链） [中等置信度] | https://menfem.com/companies/tessera |
| 认证 | 未说明 [中等置信度] | https://menfem.com/companies/tessera |

独立来源: menfem.com, usearch.com

## 技术

- [基因组编辑](https://cn.bioecon.ru/technology/genome-editing/)